Recent advances in the diagnosis and management of primary myelofibrosis

키워드

참고문헌 (64)

1. Vardiman JW, "The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes", Blood, 114, pp.937~951 (2009)[DOI]
2. Cervantes F, "New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment", Blood, 113, pp.2895~2901 (2009)[DOI]
3. Vannucchi AM, "Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up", Ann Oncol, 26(Suppl 5), pp.v85~v99 (2015)[DOI]
4. Tefferi A, "Myeloproliferative neoplasms: a decade of discoveries and treatment advances", Am J Hematol, 91, pp.50~58 (2016)[DOI]
5. Cervantes F, "Life expectancy and prognostic factors in the classic BCR", ABL-negative myeloproliferative disorders, 2008, pp.22, 905~914
6. Tefferi A, "Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis", Blood, 124, pp.2507~2513 (2014)[DOI]
7. Dupriez B, "Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system", Blood, 88, pp.1013~1018 (1996)
8. Cervantes F, "Identification of 'short-lived' and 'long-lived' patients at presentation of idiopathic myelofibrosis", Br J Haematol, 97, pp.635~640 (1997)[DOI]
9. Cervantes F, "Improving survival trends in primary myelofibrosis: an international study", J Clin Oncol, 30, pp.2981~2987 (2012)[DOI]
10. Hultcrantz M, "Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study", J Clin Oncol, 30, pp.2995~3001 (2012)[DOI]
11. Tefferi A, "Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management", Am J Hematol, 89, pp.915~925 (2014)[DOI]
12. Shammo JM, "Mutations in MPNs: prognostic implications, window to biology, and impact on treatment decisions", Hematology Am Soc Hematol Educ Program, 2016, pp.552~560 (2016)
13. Passamonti F, "Update from the latest WHO classification of MPNs: a user's manual", Hematology Am Soc Hematol Educ Program, 2016, pp.534~542 (2016)
14. Spivak JL, "Myeloproliferative neoplasms", N Engl J Med, 376, pp.2168~2181 (2017)[DOI]
15. Baxter EJ, "Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders", Lancet, 365, pp.1054~1061 (2005)[DOI]
16. James C, "A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera", Nature, 434, pp.1144~1148 (2005)[DOI]
17. Kralovics R, "A gain-of-function mutation of JAK2 in myeloproliferative disorders", N Engl J Med, 352, pp.1779~1790 (2005)[DOI]
18. Levine RL, "Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis", Cancer Cell, 7, pp.387~397 (2005)[DOI]
19. Pardanani AD, "MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients", Blood, 108, pp.3472~3476 (2006)[DOI]
20. Pikman Y, "MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia", PLoS Med, 3, pp.e270~ (2006)[DOI]
21. Klampfl T, "Somatic mutations of calreticulin in myeloproliferative neoplasms", N Engl J Med, 369, pp.2379~2390 (2013)[DOI]
22. Nangalia J, "Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2", N Engl J Med, 369, pp.2391~2405 (2013)[DOI]
23. Arber DA, "The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia", Blood, 127, pp.2391~2405 (2016)[DOI]
24. Cervantes F, "How I treat myelofibrosis", Blood, 124, pp.2635~2642 (2014)[DOI]
25. Geyer HL, "Therapy for myeloproliferative neoplasms: when, which agent, and how?", Blood, 124, pp.3529~3537 (2014)[DOI]
26. Harrison CN, "Current treatment algorithm for the management of patients with myelofibrosis, JAK inhibitors, and beyond", Hematology Am Soc Hematol Educ Program, 2017, pp.489~497 (2017)
27. Verstovsek S, "Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I", Haematologica, 100, pp.479~488 (2015)[DOI]
28. Takenaka K, "Clinical features and outcomes of patients with primary myelofibrosis in Japan: report of a 17-year nationwide survey by the Idiopathic Disorders of Hematopoietic Organs Research Committee of Japan", Int J Hematol, 105, pp.59~69 (2017)[DOI]
29. Moulard O, "Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union", Eur J Haematol, 92, pp.289~297 (2014)[DOI]
30. Deadmond MA, "Changing incidence of myeloproliferative neoplasms: trends and subgroup risk profiles in the USA, 1973-2011", J Cancer Res Clin Oncol, 141, pp.2131~2138 (2015)[DOI]
31. Geyer HL, "Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients", Blood, 123, pp.3803~3810 (2014)[DOI]
32. Emanuel RM, "Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs", J Clin Oncol, 30, pp.4098~4103 (2012)[DOI]
33. Verstovsek S, "A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis", N Engl J Med, 366, pp.799~807 (2012)[DOI]
34. Mesa RA, "Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial", J Clin Oncol, 31, pp.1285~1292 (2013)[DOI]
35. Harrison CN, "Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy", Br J Haematol, 162, pp.229~239 (2013)[DOI]
36. Gangat N, "DIPSS plus: a refined dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status", J Clin Oncol, 29, pp.392~397 (2011)
37. Passamonti F, "A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)", Blood, 115, pp.1703~1708 (2010)[DOI]
38. Daitoku S, "Calreticulin mutation does not contribute to disease progression in essential thrombocythemia by inhibiting phagocytosis", Exp Hematol, 44, pp.817~825 (2016)[DOI]
39. Tefferi A, "CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients", Leukemia, 28, pp.1494~1500 (2014)[DOI]
40. Tefferi A, "CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons", Leukemia, 28, pp.1472~1477 (2014)[DOI]
41. Mascarenhas J, "Looking forward: novel therapeutic approaches in chronic and advanced phases of myelofibrosis", Hematology Am Soc Hematol Educ Program, 2015, pp.329~339 (2015)
42. Rumi E, "Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms", Blood, 129, pp.680~692 (2017)[DOI]
43. Rozovski U, "An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis", Haematologica, 102, pp.79~84 (2017)[DOI]
44. Vannucchi AM, "Mutations and prognosis in primary myelofibrosis", Leukemia, 27, pp.1861~1869 (2013)[DOI]
45. Guglielmelli P, "The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients", Leukemia, 28, pp.1804~1810 (2014)[DOI]
46. Cervantes F, "Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: long-term results in 30 patients", Br J Haematol, 129, pp.771~775 (2005)[DOI]
47. Tefferi A, "How I treat myelofibrosis", Blood, 117, pp.3494~3504 (2011)[DOI]
48. Tefferi A, "Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients", Blood, 95, pp.2226~2233 (2000)
49. Barbui T, "Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study", J Clin Oncol, 29, pp.3179~3184 (2011)[DOI]
50. Elliott MA, "Splenic irradiation for symptomatic splenomegaly associated with myelofibrosis with myeloid metaplasia", Br J Haematol, 103, pp.505~511 (1998)[DOI]
51. Harrison C, "JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis", N Engl J Med, 366, pp.787~798 (2012)[DOI]
52. Harrison CN, "Longterm findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis", Leukemia, 30, pp.1701~1707 (2016)[DOI]
53. Vannucchi AM, "A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis", Haematologica, 100, pp.1139~1145 (2015)[DOI]
54. Heine A, "The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo", Blood, 122, pp.1192~1202 (2013)[DOI]
55. Ballen KK, "Outcome of transplantation for myelofibrosis", Biol Blood Marrow Transplant, 16, pp.358~367 (2010)[DOI]
56. Guardiola P, "Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Societe Francaise de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study", Blood, 93, pp.2831~2838 (1999)
57. Kroger NM, "Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT", ELN international working group, 2015, pp.29, 2126~2133
58. Merup M, "Different outcome of allogeneic transplantation in myelofibrosis using conventional or reduced-intensity conditioning regimens", Br J Haematol, 135, pp.367~373 (2006)[DOI]
59. Patriarca F, "Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO)", Haematologica, 93, pp.1514~1522 (2008)[DOI]
60. Gupta V, "A retrospective comparison of conventional intensity conditioning and reduced-intensity conditioning for allogeneic hematopoietic cell transplantation in myelofibrosis", Bone Marrow Transplant, 44, pp.317~320 (2009)[DOI]
61. Kroger N, "Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation", Blood, 114, pp.5264~5270 (2009)[DOI]
62. Abelsson J, "The outcome of allo-HSCT for 92 patients with myelofibrosis in the Nordic countries", Bone Marrow Transplant, 47, pp.380~386 (2012)[DOI]
63. McLornan DP, "Allogeneic stem cell transplantation for myelofibrosis in 2012", Br J Haematol, 157, pp.413~425 (2012)[DOI]
64. Ballinger TJ, "How we manage JAK inhibition in allogeneic transplantation for myelofibrosis", Eur J Haematol, 94, pp.115~119 (2015)[DOI]

관련 논문AI추천